Selective estrogen receptor modulators and postmenopausal women's health

Journal of Women's Health

Volumn 6, Issue 5, 1997, Pages 523-531

  Hol, Thorwald ^a   Cox, Martha B ^a   Bryant, Henry U ^a   Draper, Michael W ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIOPHENE DERIVATIVE; ESTROGEN; ESTROGEN RECEPTOR; INTERLEUKIN 6; RALOXIFENE;

BINDING AFFINITY; BREAST CANCER; CARDIOVASCULAR DISEASE; ESTROGEN THERAPY; FEMALE; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; UTERUS CANCER;

EID: 37849189323     PISSN: 10597115     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.1997.6.523     Document Type: Review

References (64)

1. Levrant SG, Barnes RB. Pharmacology of estrogens. In: Lobo RA, ed. Treatment of the postmenopausal woman: Basic and clinical aspects. New York: Raven Press, 1994:57.
2. Lindsay R. Estrogens, bone mass, and osteoporotic fracture. Am J Med 1991;91(Suppl 5B):10S.
3. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, 1994.
4. Riggs BL. Overview of osteoporosis. West J Med 1991;154:63.
5. Peck WA, Riggs BL, Bell NH, et al. Research directions in osteoporosis. Am J Med 1988;84:275.
6. Brainsky A, Glick H, Lydick E, et al. The economic cost of hip fractures in community-dwelling older adults: A prospective study. J Am Geriatr Soc 1997;45:281.
7. Bush TL. The epidemiology of cardiovascular disease in postmenopausal women. Ann NY Acad Sci 1990; 592:262.
8. Australian National Heart Foundation. Heart facts report, 1986.
9. Byyny RL, Speroff L. A clinical guide for the care of older women: Primary and preventive care, 2nd ed. Baltimore: Williams & Wilkins, 1996.
10. Olshansky SJ, Carnes BA, Cassel CK. The aging of the human species. Sci Am 1993;268:46.
11. Friedman E. An unfinished revolution: Women and health in America. New York: United Hospital Fund, 1994:13.
12. Lindsay R, Aitken JM, Anderson JB. Long-term prevention of postmenopausal osteoporosis by estrogen. Lancet 1976;1:1038.
13. Compston JE. HRT and osteoporosis. Br Med Bull 1992;48:309.
14. Barzel US. Estrogens in the prevention and treatment of postmenopausal osteoporosis: A review. Am J Med 1988;85:847.
15. Lindsay R. Why do estrogens prevent bone loss? Baillieres Clin Obstet Gynaecol 1991;5:837.
16. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141.
17. Barret-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861.
18. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiological evidence. Prev Med 1991;20:47.
19. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 1997;349:458.
20. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589.
21. Stanford JL, Weiss NS. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137.
22. Cauley JA, Lucas FL. Bone mineral density and risk of breast cancer in older women. JAMA 1996;276: 1404.
23. Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 1997;336:612.
24. Ravnikar VA. Compliance with hormone replacement therapy: Are women receiving the full impact of hormone replacement therapy preventative health benefits? Women's Health Issues 1992;2:75.
25. Kauffman RF, Bryant HU. Selective estrogen receptor modulators. Drug News Perspect 1995;8:531.
26. Furr BJA, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984;25:127.
27. Jones CD, Jevnikar MG, Pike AJ, et al. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b] thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem 1984;27:1057.
28. Glasebrook AL, Phillips DL, Sluka JP. Multiple binding sites for the anti-estrogen raloxifene. J Bone Miner Res 1993;8(Suppl 1):S268.
29. Sato M, McClintock C, Kim J, et al. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J Bone Miner Res 1994;9:715.
30. Sato M, Kim J, Short LL, Slemenda CW, Bryant HU. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. J Pharmacol Exp Ther 1995;272:1252.
31. Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 1994;135:2001.
32. Bryant HU, Turner CH, Frolik CA, et al. Long-term effects of raloxifene (LY139478 HC1) on bone, cholesterol and uterus in ovariectomized rats. Bone 1995;16(Suppl):116S.
33. Evans G, Bryant HU, Magee D, Sato M, Turner RT. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 1994; 134:2283.
34. Evans G, Magee D, Bryant HU, Turner RT. Raloxifene is as effective as estrogen in preventing further bone loss in mature rats with established bone loss. Endocrinology 1996;137:4139.
35. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. Time dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effects of raloxifene HC1, tamoxifen, estrogen and alendronate. Bone 1996;18:621.
36. Jerome CP, Lees CJ. Raloxifene increases bone mass and reduces bone turnover in ovariectomized cynomolgus monkeys. J Bone Miner Res 1996;11 (Suppl 1):S445.
37. Bryant HU, Magee DE, Cole HW, et al. Beneficial effects of ethynyl estradiol and raloxifene in the ovariectomized rat are dependent on an intact pituitary. J Bone Miner Res 1994;9(Suppl 1):S135.
38. Magee DE, Cole HW, Brown CE, Bryant HU. Raloxifene and estrogen retain anti-osteopenic activity in ovariectomized rats fed a low calcium diet. J Bone Miner Res 1994;9(Suppl 1):S198.
39. Bryant HU, Black LJ, Rowley ER, Sato M, Cullinan GJ. Medroxyprogesterone augments the bone effects of estrogen or raloxifene in the ovariectomized rat. Proceedings of the 77th Annual Meeting of the Endocrine Society, June 14-17, 1995, Washington DC. Bethesda: The Endocrine Society Press, 1995:596 [Abstract P3-509].
40. Bryant HU, Cole HW, Adrian MD, Wilson PK, Sato M. Raloxifene and estrogen preserve PTH induced bone mass in ovariectomized rats. FASEB J 1996;10: A469.
41. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: Medication by interleukin-6. Science 1992;257:88.
42. Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine or estrogen effects on reproductive and non-reproductive tissues in ovariectomized rats. FASEB J 1996;10:1.
43. Glasebrook AL, Short LL, Cole HW, Magee DE, Bryant HU. Regulation of serum IL-6 by raloxifene in an ovariectomized rat model. Bone 1995;16(Suppl 1):99S.
44. Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HC1) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63.
45. Brown MS, Goldstein JL. The estradiol-stimulated lipoprotein receptor of rat liver. J Biol Chem 1980;255: 10464.
46. Kauffman RF, Bensch WR, Roudebush RE, et al. Hypocholesterolemic activity of raloxifene (LY139481): Pharmacological characterization as a selective estrogen receptor modulator (SERM). J Pharmacol Exp Ther 1996;280:146.
47. Bjarnason NH, Haarbo J, Byrjalsen I, Christiansen C. Raloxifene inhibits aortic cholesterol accumulation in ovariectomized, cholesterol-fed rabbits. Atherosclerosis. 1997, in press.
48. Zuckerman SH, Bryan-Poole N. Inhibition of LDL oxidation and myeloperoxidase-dependent tyrosyl radical formation by the selective estrogen receptor modulator (LY139481 HC1). Atherosclerosis 1996;126:65.
49. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene-derived anti-estrogen. Life Sci 1983;32:1031.
50. Bryant HU, Wilson PK, Adrian MD, et al. Selective estrogen receptor modulators: Pharmacological profile in the rat uterus. J Soc Gynecol Invest 1996;3:152A.
51. Fuchs-Young R, Magee DE, Adrian MD, Termine JD, Bryant H. Raloxifene, a selective estrogen receptor modulator, inhibits the uterotrophic effect of tamoxifen over a 21-day time course. J Soc Gynecol Invest 1996;3:153A.
52. Short LL, Glasebrook AL, Adrian MD, et al. Distinct effects of selective estrogen receptor modulators on estrogen dependent and estrogen independent human breast cancer cell proliferation. J Bone Miner Res 1996;11(Suppl 1):S482.
53. Wiznitzer I, Benz C. Tamoxifen versus LY156758 for treatment of human breast and prostate cancer in vitro. Breast Cancer Res Treat 1983;3:305.
54. Labrie F, Poulin R, Simard J, et al. Interactions between estrogens, androgens, progestins and glucocorticoids in ZR-75-1 human breast cancer cells. Ann NY Acad Sci 1990;595:130.
55. Labrie F, Veilleux R, Fournier A. Glucocorticoids stimulate the growth of mouse mammary carcinoma Shionogi cells in culture. Mol Cell Endocrinol 1988;58:207.
56. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 1987;47:4020.
57. Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a new antiestrogen, keoxifene LY156758, on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 1983;32:2869.
58. Delmas PD, Bjamason NH, Mitlak B, et al. Raloxifene HC1 prevents bone loss and lowers serum cholesterol without endometrial stimulation in early postmenopausal women. Proceedings of the 79th Annual Meeting of the Endocrine Society, June 11-14, 1997, Minneapolis, MN. Bethesda: The Endocrine Society Press, 1997:67 [Abstract OR4-1].
59. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HC1: Impact on bone turnover and serum lipid profiles in healthy, postmenopausal women. J Bone Miner Res 1996;11:835.
60. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 1995;9:659.
61. 3 expression in rat bone: A potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology 1996;137:2075.
62. Kuiper GGJM, Enmark E, Pelt-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel estrogen receptor expressed in rat prostate. Proc Natl Acad Sci USA 1996;93:5925.
63. Kumar V, Green S, Jin JR, Chambon R. Functional domains of the human estrogen receptor. Cell 1987;51:941.
64. Yang NN, Venugopalan M, Hardikar S. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 1996; 273:1222.